Indication:

Treatment of relapsed/refractory acute myeloid leukemia (AML) with an IDH2 mutation (confirmed by testing).

Dosage & Administration:

·       Standard dose: 50mg once daily, taken orally (by mouth).

·       Take with or without food.

·       Swallow the tablet whole—do not crush, split, or chew.

·       If a dose is missed, take it as soon as possible unless the next dose is due within 12 hours. Do not double the dose.

Precautions:

·       Monitor for Differentiation Syndrome (fever, cough, shortness of breath, rapid weight gain, bone pain). This is a medical emergency—contact your doctor immediately if symptoms occur.

·       Liver function tests (LFTs) must be checked before and during treatment (risk of hepatotoxicity).

·       Tumor Lysis Syndrome (TLS): Increased risk in patients with high tumor burden; ensure hydration and monitor electrolytes.

·       Pregnancy/Fertility: Enasidenib may harm the fetus. Use effective contraception (both males and females).

Common Side Effects:

·       Nausea, diarrhea, decreased appetite

·       Elevated bilirubin, calcium, or potassium levels

·       Fatigue, rash

Storage:

Keep at room temperature, away from moisture and heat.

Note:  Always follow your healthcare provider’s instructions and report any side effects promptly.